A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
This early-stage clinical trial is testing a new experimental medication called NXP900 in people with advanced solid tumor cancers. Researchers want to find the safest and most effective dose of this new drug for patients whose standard treatments are no longer working.
Adults aged 18 and older with advanced solid tumors that can be measured on scans may be eligible. Participants must be well enough to handle daily activities and meet specific health and treatment history requirements.
Participants will receive the experimental study medication, NXP900, while doctors carefully monitor their health, side effects, and how their tumor responds. You will also need to agree to regular check-ups and follow safety guidelines regarding birth control.
The study has locations in Phoenix, Arizona; La Jolla, California; and Denver, Colorado. Please note that this study is currently active but not actively recruiting new participants at this time.
- 1Testing a new experimental drug named NXP900 for advanced cancers
- 2Designed for adults whose standard treatments have stopped working
- 3Currently active across three locations in the United States, but not actively recruiting new participants
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.